Metabolic reprogramming supports the invasive phenotype in malignant melanoma

Cancer Letters

Volumn 366, Issue 1, 2015, Pages 71-83

  Bettum, Ingrid J ^a   Gorad, Saurabh S ^b,c   Barkovskaya, Anna ^a   Pettersen, Solveig ^a   Moestue, Siver A ^b,c   Vasiliauskaite, Kotryna ^a   Tenstad, Ellen ^a,d   Øyjord, Tove ^a   Risa, Øystein ^b,c   Nygaard, Vigdis ^a   Mælandsmo, Gunhild M ^a,d,e   Prasmickaite, Lina ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Melanoma; Metabolic reprogramming; Phenotype switch; S100A4; Warburg effect

Indexed keywords

PROTEIN S 100; S100A4 PROTEIN, HUMAN;

CELL MOTION; DRUG EFFECTS; GLYCOLYSIS; HUMAN; MELANOMA; METABOLISM; MITOCHONDRION; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; GLYCOLYSIS; HUMANS; MELANOMA; MITOCHONDRIA; NEOPLASM INVASIVENESS; PHENOTYPE; S100 PROTEINS;

EID: 84937513716     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.06.006     Document Type: Article

References (44)

1. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest 2009, 119:1420-1428.
2. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
3. Hendrix M.J.C., Seftor E.A., Hess A.R., Seftor R.E.B. Molecular plasticity of human melanoma cells. Oncogene 2003, 22:3070-3075.
4. Jeffs A.R., Glover A.C., Slobbe L.J., Wang L., He S., Hazlett J.A., et al. A gene expression signature of invasive potential in metastatic melanoma cells. PLoS ONE 2009, 4:e8461.
5. Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006, 19:290-302.
6. Tap W.D., Gong K.-W., Daring J., Tseng Y., Ginther C., Pauletti G., et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 2010, 12:637-649.
7. Hoek K.S., Eichhoff O.M., Schlegel N.C., Dobbeling U., Kobert N., Schaerer L., et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008, 68:650-656.
8. Pinner S., Jordan P., Sharrock K., Bazley L., Collinson L., Marais R., et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res 2009, 69:7969-7977.
9. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
10. Donato R., Cannon B.R., Sorci G., Riuzzi F., Hsu K., Weber D.J., et al. Functions of S100 Proteins. Curr. Mol. Med 2013, 13:24-57.
11. Andersen K., Nesland J.M., Holm R., Florenes V.A., Fodstad O., Maelandsmo G.M. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod. Pathol 2004, 17:990-997.
12. Cabezon T., Celis J.E., Skibshoj I., Klingelhofer J., Grigorian M., Gromov P., et al. Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int. J. Cancer 2007, 121:1433-1444.
13. Ambartsumian N., Klingelhofer J., Grigorian M., Christensen C., Kriajevska M., Tulchinsky E., et al. The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene 2001, 20:4685-4695.
14. Schmidt-Hansen B., Ornas D., Grigorian M., Klingelhofer J., Tulchinsky E., Lukanidin E., et al. Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 2004, 23:5487-5495.
15. Bettum I.J., Vasiliauskaite K., Nygaard V., Clancy T., Pettersen S.J., Tenstad E., et al. Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties. Cancer Lett 2014, 344:28-39.
16. Lukanidin E., Sleeman J.P. Building the niche: the role of the S100 proteins in metastatic growth. Semin. Cancer Biol 2012, 22:216-225.
17. Schmidt-Hansen B., Klingelhöfer J., Grum-Schwensen B., Christensen A., Andresen S., Kruse C., et al. Functional significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay. J. Biol. Chem 2004, 279:24498-24504.
18. Berge G., Pettersen S., Grotterød I., Bettum I.J., Boye K., Mælandsmo G.M. Osteopontin - an important downstream effector of S100A4-mediated invasion and metastasis. Int. J. Cancer 2011, 129:780-790.
19. Rasanen K., Sriswasdi S., Valiga A., Tang H.Y., Zhang G., Perego M., et al. Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. Mol. Cell. Proteomics 2013, 12:3778-3792.
20. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
21. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
22. Lu J., Tan M., Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett 2014, 356:156-164.
23. LeBleu V.S., O'Connell J.T., Gonzalez Herrera K.N., Wikman H., Pantel K., Haigis M.C., et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol 2014, 16:992-1003.
24. Liu W., Beck B.H., Vaidya K.S., Nash K.T., Feeley K.P., Ballinger S.W., et al. Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis. Cancer Res 2014, 74:954-963.
25. Haq R., Shoag J., Andreu-Perez P., Yokoyama S., Edelman H., Rowe G.C., et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 2013, 23:302-315.
26. Vazquez F., Lim J.-H., Chim H., Bhalla K., Girnun G., Pierce K., et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013, 23:287-301.
27. Prasmickaite L., Skrbo N., Høifødt H.K., Suo Z., Engebråten O., Gullestad H.P., et al. Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells. Pigment Cell Melanoma Res 2010, 23:449-451.
28. Austdal M., Skråstad R.B., Gundersen A.S., Austgulen R., Iversen A.-C., Bathen T.F. Metabolomic biomarkers in serum and urine in women with preeclampsia. PLoS ONE 2014, 9:e91923.
29. Fan T.W.M. Metabolite profiling by one- and two-dimensional NMR analysis of complex mixtures. Prog. Nucl. Magn. Reson. Spectrosc 1996, 28:161-219.
30. Nygaard V., Prasmickaite L., Vasiliauskaite K., Clancy T., Hovig E. Melanoma brain colonization involves the emergence of a brain-adaptive phenotype. Oncoscience 2014, 1:82-94.
31. Wu Y., Siadaty M.S., Berens M.E., Hampton G.M., Theodorescu D. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 2008, 27:6679-6689.
32. Michelakis E.D., Webster L., Mackey J.R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br. J. Cancer 2008, 99:989-994.
33. D'Errico I., Salvatore L., Murzilli S., Lo Sasso G., Latorre D., Martelli N., et al. Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:6603-6608.
34. Sherwood V., Chaurasiya S.K., Ekström E.J., Guilmain W., Liu Q., Koeck T., et al. WNT5A-mediated β-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis 2014, 35:784-794.
35. Manola J., Atkins M., Ibrahim J., Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of eastern cooperative oncology group trials. J. Clin. Oncol 2000, 18:3782-3793.
36. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol 2009, 27:6199-6206.
37. Davison C.A., Durbin S.M., Thau M.R., Zellmer V.R., Chapman S.E., Diener J., et al. Antioxidant enzymes mediate survival of breast cancer cells deprived of extracellular matrix. Cancer Res 2013, 73:3704-3715.
38. Martinez-Zaguilan R., Seftor E.A., Seftor R.E., Chu Y.W., Gillies R.J., Hendrix M.J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis 1996, 14:176-186.
39. Colegio O.R., Chu N.Q., Szabo A.L., Chu T., Rhebergen A.M., Jairam V., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014, 513:559-563.
40. Folmes C.D., Nelson T.J., Dzeja P.P., Terzic A. Energy metabolism plasticity enables stemness programs. Ann. N. Y. Acad. Sci 2012, 1254:82-89.
41. Madhok B.M., Yeluri S., Perry S.L., Hughes T.A., Jayne D.G. Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells. Br. J. Cancer 2010, 102:1746-1752.
42. Doherty J.R., Cleveland J.L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest 2013, 123:3685-3692.
43. Abildgaard C., Dahl C., Basse A.L., Ma T., Guldberg P. Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition. J. Transl. Med 2014, 12:247-259.
44. Kluza J., Corazao-Rozas P., Touil Y., Jendoubi M., Maire C., Guerreschi P., et al. Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res 2012, 72:5035-5047.